Glucocorticoid resistance in paediatric acute lymphoblastic leukaemia

被引：45
|
作者：
Bhadri, Vivek A. [1 ,2 ]
Trahair, Toby N. [2 ]
Lock, Richard B.
机构：
[1] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Sydney Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW 2031, Australia
来源：
JOURNAL OF PAEDIATRICS AND CHILD HEALTH | 2012年 / 48卷 / 08期
基金：
英国医学研究理事会;
关键词：
glucocorticoid; haematology; leukaemia; oncology; GAMMA-SECRETASE INHIBITORS; MESSENGER-RNA EXPRESSION; INDUCED APOPTOSIS; BH3-ONLY PROTEINS; CELL-DEATH; RECEPTOR-ALPHA; CHILDHOOD; THERAPY; GENE; DEXAMETHASONE;
D O I：
10.1111/j.1440-1754.2011.02212.x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
Glucocorticoids (GCs), such as prednisolone and dexamethasone, are key components in multi-agent chemotherapy protocols used for the treatment of acute lymphoblastic leukaemia (ALL). Approximately 10% of children with ALL will respond poorly to GCs, and GC resistance is associated with a significantly inferior outcome. This review summarises the current knowledge of GC resistance in ALL, including the roles of the GC receptor and its co-chaperone molecules, the pro-apoptotic and pro-survival B-cell lymphoma 2 family members and alternative non-apoptotic mechanisms of cell death. It concludes with a discussion on therapeutic attempts to overcome GC resistance.
引用
收藏
页码：634 / 640
页数：7
相关论文
共 50 条
  • [21] T-cell therapy for paediatric acute lymphoblastic leukaemia
    Lokody, Isabel
    LANCET ONCOLOGY, 2014, 15 (12): : E536 - E536
  • [22] Two types of conditioning for HSCT in paediatric acute lymphoblastic leukaemia
    Minakovskaya, N.
    Kirsanova, N.
    Aleinikova, O.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S103 - S103
  • [23] Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia
    Stankovic, Tatjana
    Marston, Eliot
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2008, 136 (3-4) : 187 - 192
  • [24] Clofarabine in paediatric patients with acute lymphoblastic leukaemia: profile report
    Drugs & Therapy Perspectives, 2006, 22 (4) : 3 - 5
  • [25] Circulating microRNAs as potential biomarkers in paediatric acute lymphoblastic leukaemia
    Rzepiel, Andrea
    Kutszegi, Nora
    Egyed, Balint
    Gezsi, Andras
    Sagi, Judit C.
    Szalai, Csaba
    Semsei, Agnes F.
    Erdelyi, Daniel J.
    MOLECULAR CYTOGENETICS, 2019, 12
  • [26] Influence of wild-type MLL on glucocorticoid sensitivity and response to DNA-damage in paediatric acute lymphoblastic leukaemia
    Beesley, A. H.
    Rampellini, J. L.
    Palmer, M. L.
    Lee, J. Y. S.
    Firth, M. J.
    Kees, U. R.
    EJC SUPPLEMENTS, 2010, 8 (05): : 129 - 130
  • [27] Increased leukaemia cell stiffness is associated with symptoms of leucostasis in paediatric acute lymphoblastic leukaemia
    Lam, Wilbur A.
    Rosenbluth, Michael J.
    Fletcher, Daniel A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) : 497 - 501
  • [28] Validation of the 'French Acute Lymphoblastic Leukaemia Study Group FRALLE prognostic index' for paediatric Philadelphia-chromosome acute lymphoblastic leukaemia
    Rives, Susana
    Camos, Mireia
    Estella, Jesus
    Gomez, Pedro
    Lopez-Duarte, Monica
    Navajas, Aurora
    Badell, Isabel
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (02) : 284 - 286
  • [29] Glucocorticoid-induced apoptosis and glucocorticoid resistance in acute lymphoblastic leukemia
    Ploner, C
    Schmidt, S
    Presul, E
    Renner, K
    Schröcksnadel, K
    Rainer, J
    Riml, S
    Kofler, R
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2005, 93 (2-5): : 153 - 160
  • [30] DasatinibAcquired resistance in acute lymphoblastic leukaemia: case report
    Reactions Weekly, 2019, 1734 (1) : 173 - 173
12345